NCT04674553 is a clinical trial in Obesity, sponsored by Services Institute of Medical Sciences, Pakistan.

Who is sponsoring NCT04674553?

NCT04674553 is sponsored by Services Institute of Medical Sciences, Pakistan.

What condition does NCT04674553 study?

NCT04674553 studies Obesity, Covid19.

Is NCT04674553 still recruiting?

NCT04674553 is currently completed. Last updated 19 December 2020.

Last reviewed 2020-12-19 · How we verify

NCT04674553

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Obesity Among COVID-19 Patients in Critical Care Settings

Completed Last updated 19 December 2020

What this trial tests

trial in Obesity in 100 participants. Completed in 10 December 2020.

Timeline

10 November 2020

Primary endpoint
10 December 2020

10 December 2020

Quick facts

Lead sponsor	Services Institute of Medical Sciences, Pakistan
Status	Completed
Study type	OBSERVATIONAL
Enrollment	100
Start date	10 November 2020
Primary completion	10 December 2020
Estimated completion	10 December 2020
Sites	1 location across Pakistan

Conditions studied

Obesity — all drugs for Obesity →
Covid19 — all drugs for Covid19 →

Sponsor

Services Institute of Medical Sciences, Pakistan

Who can join

Adults 18 to 80, any sex, with Obesity or Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A novel human coronavirus that is now named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (formerly called HCoV-19) emerged in Wuhan, China, in late 2019 and is now causing a pandemic. Human-to-human transmission is primarily achieved through close contact of respiratory droplets, direct contact with the infected individuals, or by contact with contaminated objects and surfaces. As a new chapter in human life opens up, the world seems to be divided into two parts pre- and post-COVID-19 era. Body mass index (BMI) is widely used to define obesity and overweight in adults. A BMI between 25 and 30 indicates overweight and above 30 indicates obesity. It is important to note that the levels of the inflammatory cytokines found in obese people are significantly higher than those in lean people, but they are still lower than those in individuals with infection or trauma. Obesity-mediated alterations in the airways and immune system are extremely important at the present moment considering SARS-Cov-2 infection. This study is designed to determine the effect of overweight and obesity with outcomes of patients with moderate to severe COVID-19 infection in critical care setting. Also, to see outcomes of assisted ventilation in obese patients. This may help in establishing strong association of obesity with COVID-19 in our part of the world. This may open new treatment strategies for COVID-19 by treating obesity as an essential risk factor.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Impact of obesity and other key risk factors on adverse outcomes in COVID-19 patients in critical care settings.
Iftikhar M, Rizvi A, Zartash S, Nawaz A. · · 2025 · PMID 40469148 · DOI 10.12669/pjms.41.5.9302

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Services Institute of Medical Sciences, Pakistan trials

Trials by the same sponsor.

NCT07274319 — EFFICACY OF TRANSMUCOSAL MINIPLEITE STABILIZATION TECHNIQUE VERSUS INTRA-ARCH WIRE STABILIZATION TECHNIQUE FOR FIXATION · NA · not yet recruiting
NCT07238946 — Musculoskeletal Pain and Its Association With Stress in Medical Students · completed
NCT06720051 — Intraosseous Versus Submucosal Dexamethsone Injection in Third Molar Surgery · NA · not yet recruiting
NCT07243977 — Comparison of Microneedling Along With Topical Vitamin D3 Versus Microneedling in Alopecia Areata · NA · active not recruiting
NCT06622642 — Efficacy of Transoral Versus Transbuccal Technique for Fixation of Mandibular Angle Fracture · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04674553 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Services Institute of Medical Sciences, Pakistan
Last refreshed: 19 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04674553.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing